Jones Hill Capital LP
NEW YORK, NY
$470m in 29 US stocks at the end of 30 June 2026. The top 10 are 68.8% of the money. It changed about 59.6% of the portfolio this quarter.
Value
$470m
Stocks
29
Top 10 share
68.8%
Turnover
59.6%
What changed this quarter
New
Bought for the first time this quarter.
- Gilead SciencesGILD9.2% of the fund
- Arcutis BiotherapeuticsARQT6.1% of the fund
- Madrigal PharmaceuticalsMDGL6.0% of the fund
- Xenon PharmaceuticalsXENE4.7% of the fund
- Immunocore HldgsIMCR3.5% of the fund
- InsmedINSM2.8% of the fund
- Aclaris TherapeuticsACRS2.0% of the fund
- ImmunicIMUX1.8% of the fund
- Oric PharmaceuticalsORIC1.7% of the fund
- Syndax PharmaceuticalsSNDX1.6% of the fund
- Olema PharmaceuticalsOLMA1.5% of the fund
- Corbus Pharmaceuticals HoldingsCRBP1.3% of the fund
- Dianthus TherapeuticsDNTH1.2% of the fund
- Phathom PharmaceuticalsPHAT0.4% of the fund
- Achieve Life SciencesACHV<0.1% of the fund
Added
Bought more of a stock they already held.
- Biomarin PharmaceuticalBMRN17.4% of the fund+13%
- Relmada TherapeuticsRLMD5.4% of the fund+966%
- Trevi TherapeuticsTRVI5.3% of the fund+262%
- PharvarisPHVS5.0% of the fund+306%
- Tonix Pharmaceuticals HoldingTNXP1.7% of the fund+38%
Cut
Sold some of their stake.
- Bicara TherapeuticsBCAX5.6% of the fund-29%
- ANI PharmaceuticalsANIP4.1% of the fund-27%
- Amylyx PharmaceuticalsAMLX3.4% of the fund-44%
- Nuvalent2.6% of the fund-67%
- Capricor TherapeuticsCAPR2.2% of the fund-54%
- Vir BiotechnologyVIR1.4% of the fund-45%
- Vertex PharmaceuticalsVRTX1.2% of the fund-90%
- Enliven TherapeuticsELVN0.5% of the fund-92%
- Structure TherapeuticsGPCR0.5% of the fund-60%
Sold out
Sold their entire stake.
- VaxcytePCVX-100%
- Terns Pharmaceuticals-100%
- Ultragenyx PharmaceuticalRARE-100%
- Argenx SEARGX-100%
- Fulcrum TherapeuticsFULC-100%
- Nuvation BioNUVB-100%
- Oruka TherapeuticsORKA-100%
- Contineum TherapeuticsCTNM-100%
- VeradermicsMANE-100%
- Entrada TherapeuticsTRDA-100%
- Silence TherapeuticsSLN-100%
- ArriVent BioPharmaAVBP-100%
Holdings
- Immunocore HldgsIMCR
- Share
- 3.5%
- Value
- $16m
- Shares
- 512,856
New
- Nuvalent
- Share
- 2.6%
- Value
- $12m
- Shares
- 98,442
-67%
- Structure TherapeuticsGPCR
- Share
- 0.5%
- Value
- $2m
- Shares
- 40,567
-60%
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Biomarin PharmaceuticalBMRN | 17.4% | $82m | 1,431,590 | +13% |
| Gilead SciencesGILD | 9.2% | $43m | 343,043 | New |
| Arcutis BiotherapeuticsARQT | 6.1% | $29m | 1,089,701 | New |
| Madrigal PharmaceuticalsMDGL | 6.0% | $28m | 52,545 | New |
| Bicara TherapeuticsBCAX | 5.6% | $27m | 892,621 | -29% |
| Relmada TherapeuticsRLMD | 5.4% | $25m | 3,655,075 | +966% |
| Trevi TherapeuticsTRVI | 5.3% | $25m | 1,339,212 | +262% |
| PharvarisPHVS | 5.0% | $23m | 677,879 | +306% |
| Xenon PharmaceuticalsXENE | 4.7% | $22m | 367,900 | New |
| ANI PharmaceuticalsANIP | 4.1% | $19m | 233,808 | -27% |
| Immunocore HldgsIMCR | 3.5% | $16m | 512,856 | New |
| Amylyx PharmaceuticalsAMLX | 3.4% | $16m | 894,058 | -44% |
| InsmedINSM | 2.8% | $13m | 122,375 | New |
| Nuvalent | 2.6% | $12m | 98,442 | -67% |
| Capricor TherapeuticsCAPR | 2.2% | $10m | 420,751 | -54% |
| Aclaris TherapeuticsACRS | 2.0% | $9m | 1,759,492 | New |
| ImmunicIMUX | 1.8% | $8m | 539,814 | New |
| Oric PharmaceuticalsORIC | 1.7% | $8m | 747,313 | New |
| Tonix Pharmaceuticals HoldingTNXP | 1.7% | $8m | 625,428 | +38% |
| Syndax PharmaceuticalsSNDX | 1.6% | $7m | 340,000 | New |
| Olema PharmaceuticalsOLMA | 1.5% | $7m | 574,166 | New |
| Vir BiotechnologyVIR | 1.4% | $7m | 659,213 | -45% |
| Corbus Pharmaceuticals HoldingsCRBP | 1.3% | $6m | 653,572 | New |
| Dianthus TherapeuticsDNTH | 1.2% | $6m | 57,100 | New |
| Vertex PharmaceuticalsVRTX | 1.2% | $6m | 11,123 | -90% |
| Enliven TherapeuticsELVN | 0.5% | $3m | 49,850 | -92% |
| Structure TherapeuticsGPCR | 0.5% | $2m | 40,567 | -60% |
| Phathom PharmaceuticalsPHAT | 0.4% | $2m | 161,486 | New |
| Achieve Life SciencesACHV | <0.1% | $174,743 | 26,760 | New |
Over time and by industry
Value over time
Jun '26
Value is up 0.8% since 31 March 2026.
Where the money is
Health care93.5%
Other6.5%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.